SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis — Harm‐Jan de Grooth (2017) | RDL Network
SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis
Article 2017 en
Authors
HG
Harm‐Jan de Grooth
IG
Irma L. Geenen
AG
Armand R. J. Girbes
Abstract
1 min read
Treatment effects on Delta SOFA appear to be reliably and consistently associated with mortality in RCTs. Fixed-day SOFA was the most frequently reported outcome among the reviewed RCTs, but was not significantly associated with mortality. Based on this study, we recommend using Delta SOFA rather than Fixed-day SOFA as an endpoint in future RCTs.
Philipp K. Haber, Marc Puigvehí, Florian Castet, Vennis Lourdusamy, Robert Montal, Parissa Tabrizian, Michael Buckstein, Edward Kim, Augusto Villanueva, Myron Schwartz, Josep M. Llovet
Jameela Bahar, Amna Rahman, Grace W. Y. Wong, Rajiv Sankaranarayanan, Fozia Ahmed, Rebecca C. Taylor, Ahmet Fuat, Iain Squire, John G.F. Cleland, Professor Gregory Lip, James Gamble, Sundas Tahir Masudi, Prince Josiah Joseph, Kenneth Wong
Discussion(0)
No comments yet. Be the first to comment.